Cardiac and Pulmonary Effects of Alpha Tumor Necrosis Factor Administered by Isolation Perfusion

Balkwill F. , Lee A. , Aldam G. , Moodie E. , Thomas J.A. , Taver-nier J. , Fiers W. : Human tumor xenografts treated with human TNF alone or in combination with IF. Cancer Res., 46: 3990–3993, 1986.

Balkwill F. , Ward B.G. , Moodier , Fiers W. : Therapeutic potential of tumor necrosis factor alpha and gamma interferon in experimental human ovarian cancer. Cancer Res., 47: 4755–4758, 1987.

Battafarano R.J. , Dunn D.L. : Role of nitric oxide during sepsis. Crit. Case Med., 20: 1504–1505, 1992.

Bissonnette E.Y. , Hogaboam C.M. , Wallace J.L. , Dean Befus A. : Potentiation of tumor necrosis factor-alpha-mediated cytotoxicity of mast cells by their production of nitric oxide. J. Immunol., 147: 3060–3065, 1991.

Blick M. , Sherwin S.A. , Rosenblum M. , Gutterman J. : Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res., 47: 2986–2989, 1987.

Hauser G.J. , McIntosh J.K. , Travis W.D. , Rosenberg S.A. : Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy. Cancer Res., 50: 3503–3508, 1990.

Kilbourn R.G. , Gross S.S. , Jubran A. , Adams J. , Griffith O.W. , Levi R. , Lodato R.F. : G-Methyl-L-arginine inhibits tumor necrosis factor induced hypotension: Implications for the involvement of nitric oxide. Proc. Nath. Acad. Sci. USA 87: 3629–3632, 1990.

Krigel R. , Comus R. , Padavic K. : Phase I trials of recombinant tumor necrosis factor in patients with advanced malignancy. Proc. Am. Soc. Clin. Oncol., 6: 241, 1987.

Kuei J.H. , Taschkin D.P. , Figlin R.A. : Pulmonary toxicity of recombinant human tumor necrosis factor. Chest, 96: 334–338, 1989.

Lienard D. , Lejeune F.J. , Ewalenko P. , Delmotte J.J. : Isolation perfusion (IP) with high dose tumour necrosis factor (rTNF alpha) and chemotherapy for melanoma. In: Cytokines: Basic Principles and Clinical Applications. Romagnani S. , Abbas A.K. (Eds.), pp. 87–89, Raven Press, New York, 1990.

Lienard D. , Ewalenko P. , Delmotte J.J. , Lejeune F.J. : High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52–60, 1992.

Lienard D. , Lejeune F.J. , Ewalenko P. : In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon gamma and melphalan in isolation perfusion. World J. Surg., 16: 234–240, 1992.

Moncada S. , Palmer R.M.J. , Higgs E.A. : Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev., 43: 109–142, 1991.

Morice R.C. , Blick M.B. , Ali M.R. , Gutterman J.U. : Pulmonary toxicity of recombinant tumor necrosis factor. Chest, 96: 334–338, 1989.

Stadler L. , Brandon G. , Bentz B.S. , Brian H.G. , Di Silvio M. , Curran R.D. , Billiar T.R. , Hoffman R.A. , Simmons R.L. : Tumour necrosis factor alpha inhibits hepatocyte mitochondrial respiration. Ann. Surg., 216: 539–546, 1992.

Vaglini M. , Belli F. , Ammatuna M. , Furlan L. , Inglese M.G. , Manzi R. , Prada A. , Persiani L. , Santinami M. , Santoro N. , Cascinelli N. : Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer, 73: 483–492, 1994.

Villani F. , Bacchella L. , Bulgheroni A. , Pizzini L. , Galimberti M. , Aprile C. , Luisetti L. : Study of functional and biochemical indicators of subclinical lung damage in bleomycin treated patients. Respir. Med., 50: 327–333, 1990.